Treatment of Chikungunya Virus Disease in the Chronic Phase
Chikungunya virus disease can progress beyond the acute and subacute stages into a chronic phase with persistent joint involvement. Clinical management is guided by the specific phase of illness, with treatment objectives that are distinct at each stage.
Clinical Scenario
This protocol addresses the chronic phase of Chikungunya virus disease. At this stage, the primary treatment objectives are to limit potential joint damage, decrease the functional and psychological impact of the disease, and improve the patient's quality of life.
Treatment Approach — Partial Overview
When disease-modifying therapy initiated earlier in the course does not produce an adequate response, the protocol specifies a class of antirheumatic agents to advance to. The full selection criteria, clinical thresholds, and sequencing are available in the structured protocol.
Complete regimen, agent selection & criteria available below
References
- The clinical management of Chikungunya is based on the phase of the disease.
- The treatment objectives in this phase of illness are to limit the potential joint damage, decrease the functional and psychological impact and improve the quality of life.
- If the response is inadequate after 8–12 weeks, other DMARDs should be considered, including methotrexate, sulfasalazine, and leflunomide.
- Other DMARDs to be considered if the response to hydroxychloroquine is inadequate after 8–12 weeks.
View source ↗